Founder of Blueprint. I help companies stop sending emails nobody wants to read.
The problem with outbound isn't the message. It's the list. When you know WHO to target and WHY they need you right now, the message writes itself.
I built this system using government databases, public records, and 25 million job posts to find pain signals most companies miss. Predictable Revenue is dead. Data-driven intelligence is what works now.
Your GTM team is buying lists from ZoomInfo, adding "personalization" like mentioning a LinkedIn post, then blasting generic messages about features. Here's what it actually looks like:
The Typical Plixxent SDR Email:
Why this fails: The prospect is an expert. They've seen this template 1,000 times. There's zero indication you understand their specific situation. Delete.
Blueprint flips the approach. Instead of interrupting prospects with pitches, you deliver insights so valuable they'd pay consulting fees to receive them.
Stop: "I see you're hiring compliance people" (job postings - everyone sees this)
Start: "Your facility at 1234 Industrial Pkwy received EPA violation #2024-XYZ on March 15th" (government database with record number)
PQS (Pain-Qualified Segment): Reflect their exact situation with such specificity they think "how did you know?" Use government data with dates, record numbers, facility addresses.
PVP (Permissionless Value Proposition): Deliver immediate value they can use today - analysis already done, deadlines already pulled, patterns already identified - whether they buy or not.
These plays combine hard data with proprietary insights to create messages that demonstrate genuine understanding of the prospect's situation. Ordered by quality score - strongest plays first.
Target companies with public ESG commitments to renewable content by revealing a technical impossibility they likely haven't discovered yet - that FDA food contact compliance limits bio-based PU adhesives to 25% renewable content, making their 30% target unachievable with current chemistry.
This is an "oh shit" moment where you reveal a gap between their public commitments and technical reality. The FDA regulation reference (21 CFR 175.105) shows deep technical knowledge. Even if they don't buy from you, this prevents them from pursuing an impossible target and saves months of wasted R&D effort.
This play requires internal technical data on bio-based PU chemistry limitations mapped against FDA food contact regulations and customer application requirements.
This technical knowledge synthesis is unique to specialized PU houses with bio-based R&D capabilities.Target automotive manufacturers with public ESG commitments by analyzing their specific product SKUs against bio-based PU performance specs and certification requirements. Identify which current SKUs can convert to bio-based without re-certification and which cannot.
The SKU-level specificity shows you've analyzed their actual products, not just read their ESG report. The re-certification angle is a blind spot most companies have - they assume material swaps are simple until they discover regulatory implications. This assessment saves months of R&D time and potential compliance failures.
This play requires internal testing data on bio-based PU formulations mapped against industry-specific performance standards and certification requirements.
This synthesis of your proprietary bio-based performance data with customer product specifications creates differentiated insight.Identify companies where public ESG commitments to renewable content contradict their technical spec sheets that still reference 100% petroleum-based materials. Test their specs against bio-based alternatives and reveal which products can convert with zero performance loss versus which require spec modifications.
Finding an inconsistency between public commitments and technical specifications is sharp research that demonstrates attention to detail. The 3 of 5 breakdown provides immediate actionable intelligence. Knowing which products need spec modifications is planning insight they can use whether they buy from you or not.
This play requires internal bio-based PU testing data mapped against customer technical specifications and performance requirements.
The synthesis of public commitments, technical specs, and your proprietary testing data creates unique insight.Research a company's current PU supplier relationships and map them against bio-based product availability. Reveal that their top suppliers don't have commercial-scale bio-based offerings in their application categories, meaning they'll need new supplier relationships to hit ESG targets.
Deep supplier research demonstrates commitment to understanding their business. Identifying that current suppliers can't deliver bio-based solutions saves them from assuming existing relationships can solve the problem. The "2 new supplier relationships" finding is specific and forces them to rethink their procurement strategy.
This play requires internal competitive intelligence on supplier bio-based product portfolios mapped against customer supplier relationships and application requirements.
Your market knowledge of bio-based PU availability across competitors creates differentiated supplier intelligence.Target companies with public renewable content commitments by mapping their product lines against bio-based PU performance capabilities. Identify which applications can hit the target and which cannot with current technology, saving them from pursuing impossible conversions.
The 4 vs 2 split is concrete and immediately useful for planning. This assessment saves months of R&D exploration by telling them upfront which products are feasible candidates for bio-based conversion. Even without buying, this helps them allocate R&D resources efficiently.
This play requires internal technical data on bio-based PU performance characteristics mapped against customer product specifications.
Your proprietary bio-based formulation knowledge creates unique feasibility intelligence.Target furniture manufacturers with ESG commitments by analyzing their specific product SKUs against bio-based PU performance specs and BIFMA durability standards. Identify which SKUs cannot achieve their renewable content target without failing certification.
SKU-level analysis demonstrates deep product knowledge. The BIFMA standards reference shows technical expertise. The 6 out of 14 breakdown identifies a real problem they may not have discovered yet, preventing them from pursuing impossible conversions that waste R&D budget.
This play requires internal technical data on bio-based PU performance characteristics mapped against BIFMA standards and customer product specifications.
The synthesis of certification requirements with your bio-based capabilities creates unique SKU-level intelligence.Target footwear manufacturers with ESG commitments by connecting their renewable content targets to revenue exposure and revealing a critical supplier capability gap - their current supplier doesn't offer bio-based alternatives in footwear applications.
Connecting ESG targets to revenue mix (40% from footwear) shows business acumen. The ASTM F1976 standard reference demonstrates technical depth. Identifying that their current supplier lacks bio-based offerings is non-obvious intelligence that prompts them to expand supplier search.
This play requires internal technical data on bio-based PU capabilities mapped against industry performance standards and competitive supplier portfolio analysis.
Your market intelligence on supplier bio-based availability creates differentiated insight into supply chain gaps.Track funded companies through SEC filings, then research competitor patent activity in their application space. Reveal that competing material suppliers have filed patents recently, meaning competitors are 12-18 months ahead on formulation development.
Patent research is specific and non-obvious - most companies don't monitor competitor supplier patent activity. The timeline implications are immediately concerning and actionable. However, the competitive threat framing is slightly fear-based rather than pure value delivery.
This play requires access to patent filing analysis tools and internal formulation development timeline benchmarks.
The synthesis of patent intelligence with development timelines creates competitive pressure insight.Track funded companies and offer pattern recognition from analyzing launch delays across similar companies. Reveal that formulation iteration cycles taking 3-5 rounds instead of planned 1-2 rounds is the biggest launch delay factor.
The 47 product launches analysis provides pattern recognition value. However, the data is unverifiable and feels like industry benchmarking rather than insight specific to their situation. The decision tree offer is intriguing but vague, making the value delivery less concrete.
This play requires internal tracking data across customer projects analyzing formulation iteration patterns and success factors.
Aggregated learning from your project history creates benchmarking intelligence.Old way: Spray generic messages at job titles. Hope someone replies.
New way: Use public data and proprietary technical knowledge to find companies with specific sustainability gaps or compliance needs. Then mirror that situation back to them with evidence.
Why this works: When you lead with "Your packaging line can't hit 30% renewable due to FDA 21 CFR 175.105 compliance limits" instead of "I see you have sustainability goals," you're not another sales email. You're the technical expert who did the homework.
The messages above aren't templates. They're examples of what happens when you combine public ESG commitments with proprietary bio-based PU performance data. Your team can replicate this using the data sources in each play.
Every play traces back to verifiable data. Here are the key sources used in this playbook:
| Source | Key Fields | Used For |
|---|---|---|
| Company ESG Reports | sustainability_commitments, renewable_content_targets, target_dates | Identifying companies with renewable content commitments and target timelines |
| SEC Form 10-K Filings | revenue_by_segment, product_lines, business_risks | Understanding revenue exposure by product line and business priorities |
| SEC Series B Filings | funding_amount, funding_date, investors, use_of_proceeds | Tracking newly funded companies with budget for supplier relationships |
| FDA 21 CFR 175.105 | food_contact_compliance, approved_materials, testing_requirements | Identifying food packaging compliance constraints on bio-based materials |
| BIFMA Standards | durability_requirements, flame_retardant_specs, performance_testing | Understanding furniture certification requirements for bio-based conversions |
| ASTM F1976 | impact_absorption_standards, footwear_testing, performance_thresholds | Mapping footwear performance requirements against bio-based capabilities |
| USPTO Patent Database | patent_filings, application_categories, filing_dates, assignees | Tracking competitor supplier patent activity in customer application spaces |
| LinkedIn Company Profiles | company_size, recent_hires, supplier_relationships, executive_changes | Identifying supplier relationships and organizational changes |
| Technical Specification Sheets | material_composition, performance_requirements, certification_specs | Analyzing product specifications to identify bio-based conversion feasibility |
| Internal Bio-Based PU Database | formulation_performance, cost_premiums, certification_compatibility | Mapping bio-based capabilities against customer requirements and standards |
| Internal Formulation Timeline Data | development_cycles, iteration_counts, time_to_production | Benchmarking typical formulation development timelines by industry and complexity |
| Competitor Product Portfolio Intelligence | supplier_capabilities, bio-based_offerings, application_coverage | Identifying gaps in current supplier portfolios for bio-based solutions |